Ticker > Company >

Emcure Pharma share price

Emcure Pharmaceuticals Ltd.

NSE: EMCURE BSE: 544210 SECTOR: Pharmaceuticals & Drugs  63.98 K   48   22

1391.80
0 0
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 1428.55

Today's Low

₹ 1385

52 Week High

₹ 1577.5

52 Week Low

₹ 890

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

26375.77 Cr.

Enterprise Value

27017.34 Cr.

No. of Shares

18.95 Cr.

P/E

66.03

P/B

8.41

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  165.44

CASH

13.8 Cr.

DEBT

655.37 Cr.

Promoter Holding

77.91 %

EPS (TTM)

₹  21.08

Sales Growth

25.28%

ROE

12.86 %

ROCE

15.41%

Profit Growth

97.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Emcure Pharmaceuticals Ltd.

Orofer Bevon Zostum Ferium Exhep Metpure Maxtra Pause

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.28%
3 Year8.96%
5 Year13.02%

Profit Growth

1 Year97.18%
3 Year-10.8%
5 Year12.6%

ROE%

1 Year12.86%
3 Year10.18%
5 Year14.62%

ROCE %

1 Year15.41%
3 Year12.43%
5 Year15.58%

Debt/Equity

0.2175

Price to Cash Flow

47.24

Interest Cover Ratio

4.7863

CFO/PAT (5 Yr. Avg.)

1.89410486876457

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 77.91 0.04
Mar 2025 77.92 0.04
Dec 2024 77.94 0.00
Sep 2024 78.08 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 749.255 Cr.
  • Company’s PEG ratio is 0.745997942273012.
  • The company has an efficient Cash Conversion Cycle of -22.6333 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.89410486876457.
  • The company has a high promoter holding of 77.91%.

 Limitations

  • The company has shown a poor profit growth of -10.7988930013688% for the Past 3 years.
  • The company has shown a poor revenue growth of 8.96135592274436% for the Past 3 years.
  • The company is trading at a high PE of 66.03.
  • The company is trading at a high EV/EBITDA of 31.1448.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 970.29 1104.63 1028.81 1278.19 1096.57
Total Expenditure 850.54 952.47 904.4 1033.55 868.57
Operating Profit 119.75 152.16 124.42 244.64 228
Other Income 27.94 54.93 19.41 22.4 21.52
Interest 37.57 31.4 19.93 24.07 20.54
Depreciation 55.08 56.34 56.65 56.91 59.82
Exceptional Items 0 0 0 0 -3.5
Profit Before Tax 55.05 119.36 67.25 186.05 165.67
Tax 14.6 32.44 17.05 46.5 42.88
Profit After Tax 40.45 86.92 50.2 139.56 122.79
Adjusted EPS (Rs) 2.23 4.6 2.65 7.37 6.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 3153.66 3387.24 3107.09 3497.66 4381.92
Total Expenditure 2410.26 2592.57 2668.59 3055.76 3758.76
Operating Profit 743.41 794.67 438.49 441.89 623.17
Other Income 111.91 132.68 125.35 138.26 142.48
Interest 123.34 145.14 166.83 166.09 112.96
Depreciation 156.24 165.79 178.52 204.83 224.97
Exceptional Items -18.29 0 -6.15 -9.32 0
Profit Before Tax 557.45 616.42 212.34 199.91 427.71
Tax 136.97 169.61 52.28 39.08 110.58
Net Profit 420.48 446.81 160.06 160.83 317.13
Adjusted EPS (Rs.) 23.25 24.71 8.85 8.88 16.74

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 180.85 180.85 180.85 181.15 189.48
Total Reserves 2120.92 1531.68 1661.02 1753.95 2834.88
Borrowings 645.97 512.4 600.65 438.21 406.29
Other N/C liabilities 126.27 164.19 177 253.51 266.3
Current liabilities 1789.18 1934.06 1996.33 2130.12 1719.16
Total Liabilities 4863.2 4323.18 4615.85 4756.93 5416.11
Assets
Net Block 1277.9 1307.36 1432.71 1718.24 1759.06
Capital WIP 192.09 239.25 253.1 106.4 92.83
Intangible WIP 0 0 0 0 6.28
Investments 863.73 563.36 690.02 684 677.65
Loans & Advances 299.42 63.25 77.51 105.37 393.13
Other N/C Assets 27.38 13.92 23.01 24.91 27.11
Current Assets 2202.68 2136.05 2139.51 2118.01 2460.05
Total Assets 4863.2 4323.18 4615.85 4756.93 5416.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 557.45 616.42 212.34 199.91 427.71
Adjustment 246.72 265 309.21 325.56 284.14
Changes in Assets & Liabilities 84.38 -283.04 68.37 126.36 -87.45
Tax Paid -113.67 -170.67 -84.54 -66.86 -66.11
Operating Cash Flow 774.87 427.71 505.37 584.97 558.29
Investing Cash Flow -835.78 -393.81 -270.56 -173.08 -437.66
Financing Cash Flow 30.97 -342.96 -54.52 -287.75 -49.25
Net Cash Flow -29.94 -309.06 180.3 124.15 71.38

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 78.08 77.94 77.92 77.91
bhavana satish mehta 4.72 4.71 4.71 4.71
everest trust (shares hel... 7.68 7.67 7.66 7.66
girish harrai desai 0.06 0.06 0.06 0.06
kamini sunil mehta 0.88 0.88 0.88 0.88
namita vikas thapar 2.68 2.68 2.68 2.68
niraj sunil mehta 0.58 0.58 0.58 0.58
pushpa rajnikant mehta 2.06 2.05 2.05 2.05
ranjanakumari mukeshbhai ... 0.02 0.02 0.02 0.02
rutav sunil mehta 0.52 0.52 0.52 0.52
samit s mehta 7.16 7.15 7.14 7.14
sanjay rajanikant mehta 1.96 1.96 1.95 1.95
satish r mehta 39.87 39.80 39.79 39.79
shaila sharad gujar 0.04 0.04 0.04 0.04
smita paresh shah 0.07 0.07 0.07 0.07
suhasinee saumil shah 0.07 0.07 0.07 0.07
sunil rajanikant mehta 1.51 1.50 1.50 1.50
surekha umakant shah 0.17 0.17 0.17 0.17
swati hetalkumar shah 0.03 0.03 0.03 0.03
unity trust (shares held ... - - - 7.66
vikas m thapar 0.34 0.34 0.34 0.34
unity trust (shares held ... 7.67 7.66 7.66 -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 21.92 22.06 22.08 22.09
bc investments iv limited... 8.69 8.68 8.68 8.67
llp - 0.08 0.07 0.04

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE RATINGS
Credit CARE RATINGS
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Emcure Pharmaceuticals informs about outcome of board meeting 7 Aug, 2:57 PM Emcure Pharma - Quaterly Results 7 Aug, 1:42 PM Emcure Pharma - Quaterly Results 7 Aug, 1:42 PM Emcure Pharma - Quaterly Results 7 Aug, 1:42 PM Emcure Pharmaceuticals enters into agreement with Sanofi India 17 Jul, 9:21 AM USFDA concludes PAI at Emcure Pharmaceuticals’ Gujarat manufacturing facility 10 Jul, 10:11 AM Emcure Pharmaceuticals incorporates wholly owned subsidiary 4 Jul, 6:06 PM Emcure Pharmaceuticals informs about incorporation of WOS 4 Jul, 5:21 PM Emcure Pharmaceuticals gets nod to incorporate wholly owned subsidiary 21 Jun, 5:22 PM Emcure Pharmaceuticals informs about updates 21 Jun, 4:21 PM Emcure Pharmaceuticals informs about press release 21 Jun, 4:14 PM Emcure Pharmaceuticals informs about acquisition 21 Jun, 3:38 PM Emcure Pharmaceuticals informs about outcome of board meeting 21 Jun, 2:05 PM Emcure Pharmaceuticals gets nod for acquiring 20.42% stake of Zuventus Healthcare 21 Jun, 1:00 PM Emcure Pharmaceuticals inks pact to purchase electricity generated from TUPL 3 Jun, 12:00 PM Emcure Pharmaceuticals gets nod to incorporate wholly-owned subsidiary 23 May, 9:27 AM Emcure Pharmaceuticals informs about change in management 22 May, 5:00 PM Emcure Pharma - Quaterly Results 22 May, 2:28 PM Emcure Pharma - Quaterly Results 22 May, 2:28 PM Emcure Pharma - Quaterly Results 22 May, 2:28 PM Emcure Pharmaceuticals gets EIR for Pune manufacturing facility 21 Apr, 10:22 AM Emcure Pharmaceuticals’ arm inks pact with Manx Healthcare 4 Apr, 3:45 PM Emcure Pharmaceuticals’ arm inks in-licensing agreement with WiQo 2 Apr, 12:39 PM Emcure Pharmaceuticals expands OTC Portfolio with Arth Supplements 10 Mar, 5:45 PM Emcure Pharma - Quaterly Results 6 Feb, 3:04 PM Emcure Pharma - Quaterly Results 6 Feb, 3:04 PM Emcure Pharmaceuticals informs about press release 23 Jan, 5:36 PM Emcure Pharmaceuticals inaugurates R&D centre in Gujarat 23 Jan, 3:45 PM Emcure Pharmaceuticals informs about compliance certificate 10 Jan, 12:46 PM Emcure Pharmaceuticals informs about newspaper publication 23 Nov, 11:38 AM Emcure Pharma - Quaterly Results 7 Nov, 3:41 PM Emcure Pharma - Quaterly Results 7 Nov, 3:41 PM Emcure Pharma - Quaterly Results 7 Nov, 3:41 PM Emcure Pharmaceuticals informs about press release 3 Oct, 12:53 PM Emcure Pharmaceuticals signs agreement with Gilead Sciences Ireland UC 3 Oct, 11:30 AM Emcure Pharmaceuticals informs about closure of trading window 26 Sep, 4:32 PM Emcure Pharmaceuticals gets nod to incorporate wholly-owned subsidiary 14 Sep, 3:03 PM Emcure Pharma - Quaterly Results 13 Aug, 9:13 PM Emcure Pharmaceuticals signs Power Purchase Agreement with Sunsure Energy 26 Jul, 10:41 AM Emcure Pharmaceuticals coming with IPO to raise Rs 1993.05 crore 29 Jun, 3:56 PM Emcure Pharmaceuticals gets SEBI's go-ahead to launch IPO 15 Dec, 12:36 PM

Emcure Pharma Stock Price Analysis and Quick Research Report. Is Emcure Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Emcure Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Emcure Pharma has a PE ratio of 66.1027643232935 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Emcure Pharma has ROA of 6.2347% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Emcure Pharma has a Current ratio of 1.431.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Emcure Pharma has a ROE of 12.8618%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Emcure Pharma has a Debt to Equity ratio of 0.2175 which means that the company has low proportion of debt in its capital.

  • Sales growth: Emcure Pharma has reported revenue growth of 25.2818% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Emcure Pharma for the current financial year is 14.221287270158%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Emcure Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Emcure Pharma is Rs 21.0793. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Emcure Pharma in Ticker for free. Also, one can get the intrinsic value of Emcure Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Emcure Pharma FAQs

Q1. What is Emcure Pharma share price today?
Ans: The current share price of Emcure Pharma is Rs 1393.4.

Q2. What is the market capitalisation of Emcure Pharma?
Ans: Emcure Pharma has a market capitalisation of Rs 26406.09307098 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Emcure Pharma?
Ans: The PE ratio of Emcure Pharma is 66.1027643232935 and the P/B ratio of Emcure Pharma is 8.4221444252101, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Emcure Pharma share?
Ans: The 52-week high share price of Emcure Pharma is Rs 1580, and the 52-week low share price of Emcure Pharma is Rs 889.

Q5. Does Emcure Pharma pay dividends?
Ans: Currently, Emcure Pharma does not pay dividends. Dividend yield of Emcure Pharma is around 0%.

Q6. What are the face value and book value of Emcure Pharma shares?
Ans: The face value of Emcure Pharma shares is Rs 10, while the book value per share of Emcure Pharma is around Rs 165.4448. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Emcure Pharma?
Ans: Emcure Pharma has a total debt of Rs 655.369 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Emcure Pharma?
Ans: The ROE of Emcure Pharma is 12.8618% and ROCE of Emcure Pharma is 15.405%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Emcure Pharma a good buy for the long term?
Ans: The Emcure Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Emcure Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Emcure Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Emcure Pharma’s financials?
Ans: You can review Emcure Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Emcure Pharma
X